All Trials

Window of Opportunity Assessment of [Fam-]Trastuzumab DERuxtecan-nxki (T-DXd) Brain Tumor Penetration and Efficacy (WOnDER-BT)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with resectable brain tumors, including HER2-expressing or ERBB2-mutant brain metastases (HER2-high, HER2-low, or HER2-mutant) and HER2-expressing recurrent glioblastoma; includes patients with or without prior T-DXd. Patients receive perioperative trastuzumab deruxtecan (HER2-directed antibody-drug conjugate delivering a topoisomerase I inhibitor) to assess intratumoral penetration and preliminary efficacy.

ClinicalTrials.gov ID: NCT06058988

Phase II Trial of Adcetris (Brentuximab Vedotin) in CD30+ Malignant Mesothelioma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Single-arm study for adults with unresectable, CD30-positive malignant mesothelioma (any site/histology), previously treated or chemo‑naive, ECOG 0–2. Patients receive brentuximab vedotin IV every 21 days; this anti‑CD30 antibody-drug conjugate delivers MMAE to CD30-expressing cells, aiming for disease control with correlative biomarker analyses.

ClinicalTrials.gov ID: NCT03007030

Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with HRD-positive malignant mesothelioma (pleural, peritoneal, or tunica vaginalis) who are platinum-sensitive after prior cisplatin/carboplatin, ECOG 0–1, receive single-agent olaparib. Olaparib is an oral PARP1/2 inhibitor leveraging synthetic lethality in BAP1/HRR-deficient tumors; excludes prior PARP use and platinum-resistant disease.

ClinicalTrials.gov ID: NCT04515836

A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2D), and Efficacy of Lurbinectedin Monotherapy in Pediatric Participants With Previously Treated Solid Tumors Followed by Expansion to Assess Efficacy and Safety in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Open-label dose-escalation/expansion of lurbinectedin monotherapy for pediatric patients with previously treated solid tumors (≥2 to <18 years) to establish RP2D, followed by treatment of pediatric/young adult patients (≥2 to ≤30 years) with relapsed/refractory Ewing sarcoma. Lurbinectedin is a DNA minor-groove binder that inhibits oncogenic transcription and induces DNA double-strand breaks; key exclusions include significant QTc prolongation, active CNS disease requiring steroids, prior lurbinectedin/trabectedin, and recent intensive therapy.

ClinicalTrials.gov ID: NCT05734066

Lurbinectedin in FET-Fusion Tumors (LIFFT)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling patients ≥10 years with recurrent/relapsed solid tumors harboring FET fusions (EWSR1, FUS, TAF15), including an efficacy cohort for EWS-FLI1–positive relapsed/refractory Ewing sarcoma, to receive lurbinectedin IV on days 1 and 4 of 28-day cycles. Lurbinectedin is a selective inhibitor of oncogenic transcription that binds the DNA minor groove, suppressing fusion-driven transcription (e.g., EWS-FLI1) and tumor-associated macrophages.

ClinicalTrials.gov ID: NCT05918640

Allogeneic Stem Cell Transplantation Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion With Zoledronic Acid in Combination to Treat Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory Solid Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Pediatric, adolescent, and young adult patients (6 months–25 years) with relapsed/refractory high-risk solid tumors undergo haploidentical allogeneic HSCT using αβ T-cell and CD19+ B-cell–depleted grafts, with adjunct zoledronic acid. Zoledronic acid, a nitrogen-containing bisphosphonate that inhibits farnesyl pyrophosphate synthase and activates γδ T cells, is used to enhance graft-versus-tumor effects.

ClinicalTrials.gov ID: NCT06625190

A Phase 1/2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects With MAGE-A4 Positive Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Pediatric and young adult patients (2–17 with synovial sarcoma; 2–21 with MPNST, neuroblastoma, or osteosarcoma) with HLA‑A*02 positivity and centrally confirmed MAGE‑A4–expressing, measurable disease receive leukapheresis, fludarabine/cyclophosphamide lymphodepletion, and a single infusion of afamitresgene autoleucel. Afami‑cel is an autologous TCR-engineered T‑cell therapy targeting MAGE‑A4 presented by HLA‑A*02, with expected T‑cell therapy toxicities including CRS and cytopenias.

ClinicalTrials.gov ID: NCT05642455

A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: For patients <50 years with histologically confirmed osteosarcoma and resectable oligometastatic pulmonary disease (≤4 nodules/lung, 3 mm–3 cm) at initial presentation or first pulmonary relapse, this trial randomizes to open thoracotomy versus video-assisted thoracoscopic surgery (VATS) for metastasectomy. Key exclusions include unresectable primary tumor, central lesions needing anatomic resection, extrapulmonary metastases, significant pleural effusion, or prior therapeutic pulmonary metastasectomy.

ClinicalTrials.gov ID: NCT05235165

Phase 1b Trial of Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery in Patients With Pulmonary Recurrence of Osteosarcoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Single-arm study for children through adults with osteosarcoma limited to the lungs in first or later pulmonary relapse, with all nodules resectable and at least one SBRT-eligible lesion. Patients receive atezolizumab (anti–PD-L1) combined with SBRT to a selected lung lesion, followed by complete surgical resection of all pulmonary metastases, with perioperative atezolizumab per unilateral or bilateral disease schema.

ClinicalTrials.gov ID: NCT06492954

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors: An Open-label, Phase II, Single-arm, Multi-center Trial

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Pediatric and young adult patients (6 months–30 years) with relapsed/refractory solid tumors (excluding lymphoma), including a dedicated efficacy cohort for PD-L1–enriched, measurable rhabdomyosarcoma, eligible if adequate organ function and no prior PD-1/PD-L1 therapy. Treatment is atezolizumab (anti–PD-L1) combined with vincristine, irinotecan, and temozolomide in 21-day cycles until progression/toxicity.

ClinicalTrials.gov ID: NCT04796012